Search Results - "TUTTLE, R. L"

Regulation of pancreatic β-cell growth and survival by the serine/threonine protein kinase Akt1/PKBα by Birnbaum, Morris J, Tuttle, Robyn L, Gill, Navdeep S, Pugh, William, Lee, Jean-Pyo, Koeberlein, Brigitte, Furth, Emma E, Polonsky, Kenneth S, Naji, Ali

“…The physiological performance of an organ depends on an interplay between changes in cellular function and organ size, determined by cell growth, proliferation…”
Get full text

Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases by Neidhart, J A, Anderson, S A, Harris, J E, Rinehart, J J, Laszlo, J, Dexeus, F H, Einhorn, L H, Trump, D L, Benedetto, P W, Tuttle, R L

“…One hundred sixty-five patients were randomized to receive either interferon alfa-n1 (Wellferon; Burroughs Wellcome Co, Research Triangle Park, NC) alone or…”
Get more information

Splenectomy vs. alpha interferon: a randomized study in patients with previously untreated hairy cell leukemia by Smalley, R V, Connors, J, Tuttle, R L, Anderson, S, Robinson, W, Whisnant, J K

“…Twenty patients with previously untreated hairy cell leukemia were randomized to undergo either splenectomy or to receive interferon alfa-N1, a highly purified…”
Get more information

A phase II study of crisnatol mesylate in patients with ovarian carcinoma by SMALLEY, R. V, GOLDSTEIN, D, BULKOWSKI, D, HANNON, C, BUCHLER, D, KNUDSEN, C, TUTTLE, R. L

“…Fourteen patients with advanced ovarian cancer received a 72 hour infusion of a new DNA intercalator, crisnatol mesylate, administered intravenously. There was…”
Get full text

Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion by SCHILSKY, R. L, RATAIN, M. J, JANISCH, L, VOGELZANG, N. J, SOL LUCAS, V, RAVITCH, J, HOHNEKER, J. A, CLENDENINN, N. J, TUTTLE, R. L

“…502U83 is an arylmethylaminopropanediol that displays significant antitumor activity in a number of murine and human tumor-model systems. In the present phase…”
Get full text

Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule by HARMAN, G. S, CRAIG, J. B, WARGIN, W, WHISNANT, J. K, VON HOFF, D. D, KUHN, J. G, LUTHER, J. S, TURNER, J. N, WEISS, G. R, TWEEDY, D. A, KOELLER, J, TUTTLE, R. L, LUCAS, V. S

“…Crisnatol is a novel lipophilic arylmethylaminopropanediol with significant antineoplastic activity in a variety of murine and human tumor models which…”
Get full text

Crisnatol mesylate : phase I dose escalation by extending infusion duration by POPLIN, E. A, CHABOT, G. G, TUTTLE, R. L, WARGIN, W. A, BAKER, L. H

“…Crisnatol mesylate is a rationally designed cytotoxic arylmethylamino-propanediol with broad spectrum cytotoxic activity. A phase I study with an…”
Get full text

(1-Pyrenylmethyl)amino alcohols, a new class of antitumor DNA intercalators. Discovery and initial amine side chain structure-activity studies by Bair, K W, Tuttle, R L, Knick, V C, Cory, M, McKee, D D

“…In the series of 1-pyrenylmethylamines studied in this work the relationships among structure, interaction with DNA, and murine antitumor activity were…”
Get full text

2-[(Arylmethyl)amino]-2-methyl-1,3-propanediol DNA intercalators. An examination of the effects of aromatic ring variation on antitumor activity and DNA binding by Bair, Kenneth W, Andrews, C. Webster, Tuttle, Richard L, Knick, Vincent C, Cory, Michael, McKee, David D

“…The effects of variation of aromatic ring size, shape, and side-chain position on antitumor activity and DNA binding in a series of carbocyclic…”
Get full text

High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study by Trump, D L, Elson, P J, Borden, E C, Harris, J E, Tuttle, R L, Whisnant, J K, Oken, M M, Carignan, J R, Ruckdeschel, J C, Davis, T E

“…This report describes a phase II Eastern Cooperative Oncology Group (ECOG) study of high-dose lymphoblastoid interferon (IFN alpha-n1) in 39 patients with…”
Get more information

Evaluation of arylmethylaminopropanediols by a novel in vitro pharmacodynamic assay : correlation with antitumor activity in vivo by ADAMS, D. J, WATKINS, P. J, KNICK, V. C, TUTTLE, R. L, BAIR, K. W

“…The pharmacodynamics of a new series of antitumor DNA intercalators, known as arylmethylaminopropanediols (AMAPs), has been evaluated in vitro against adherent…”
Get full text

Mechanisms of antitumor action of Corynebacterium parvum: replicating short-lived T cells as the mediators of potentiated tumor-specific immunity by Tuttle, R L, North, R J

Get more information

Mechanisms of antitumor action of Corynebacterium parvum: the generation of cell-mediated tumor specific immunity by Tuttle, R L, North, R J

Get more information

Observations on the nature of the determinants in anaerobic coryneforms which produce splenomegaly by Cummins, C S, Stimpson, S A, Tuttle, R L, Weck, C J

Get more information

Signaling Pathways Mediating Insulin-Stimulated Glucose Transport by SUMMERS, SCOTT A., YIN, VIRAVUTH P., WHITEMAN, EILEEN L., GARZA, LUIS A., CHO, HAN, TUTTLE, ROBYN L., BIRNBAUM, MORRIS J.

“…A major action of insulin is to accelerate the rate of uptake of sugar into muscle and adipose cells following a meal. The biochemical mechanism by which this…”
Get full text

Human LATS1 is a mitotic exit network kinase by BOTHOS, John, TUTTLE, Robyn L, OTTEY, Michelle, LUCA, Francis C, HALAZONETIS, Thanos D

“…The kinase LATS/WARTS is a tumor suppressor protein conserved in evolution, but its function at the molecular level is not well understood. We report here that…”
Get full text

In vivo and in vitro antitumor activity expressed by cells of concomitantly immune mice by TUTTLE, R. L, KNICK, V. C, STOPFORD, C. R, WOLBERG, G

“…Growth of a primary tumor is often accompanied by the development of resistance to subsequent challenge implants of the same tumor, i.e., concomitant immunity…”
Get full text

A randomized comparison of two doses of human lymphoblastoid interferon-alpha in hairy cell leukemia. Wellcome HCL Study Group by Smalley, R V, Anderson, S A, Tuttle, R L, Connors, J, Thurmond, L M, Huang, A, Castle, K, Magers, C, Whisnant, J K

“…One hundred thirty-eight patients with hairy cell leukemia were randomized to receive either a dose of 2.0 megaunits (MU)/m2 or a 10-fold lower dose of 0.2…”
Get full text

Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule by VON HOFF, D. D, KUHN, J. G, WARGIN, W, HUBBELL, J, TUTTLE, R. L, KOELLER, J. M, FREEMAN, G. L, HAVLIN, K. A, LANGEVIN, A.-M, BROWN, T. D, WEISS, G. R, TURNER, J. N, PURVIS, J, SOL LUCAS, V, BAIR, K. W

“…502U83 is an arylmethylaminopropanediol derivative exhibiting significant antineoplastic activity in a number of murine and human tumor models. In this Phase I…”
Get full text

Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha by Tuttle, R L, Gill, N S, Pugh, W, Lee, J P, Koeberlein, B, Furth, E E, Polonsky, K S, Naji, A, Birnbaum, M J

“…The physiological performance of an organ depends on an interplay between changes in cellular function and organ size, determined by cell growth, proliferation…”
Get full text